Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
25.43
0.00 (0.00%)
Nov 21, 2024, 12:43 PM EST - Market open
Enliven Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -85.21 | -71.58 | -37.66 | -24.74 | -18.97 |
| Depreciation & Amortization | 0.32 | 0.3 | 0.22 | 0.12 | 0.05 |
| Other Amortization | - | - | 1.74 | - | - |
| Loss (Gain) From Sale of Investments | -2.34 | -4.6 | - | - | - |
| Stock-Based Compensation | 17.89 | 12.91 | 3.19 | 1.92 | 0.13 |
| Other Operating Activities | -0.56 | 0.31 | - | - | 9.68 |
| Change in Accounts Payable | -0.47 | -2.25 | 0.41 | 1.73 | 0.29 |
| Change in Other Net Operating Assets | 1.91 | 3.65 | 0.03 | 1.83 | 0.29 |
| Operating Cash Flow | -68.47 | -61.27 | -32.08 | -19.13 | -8.53 |
| Capital Expenditures | -0.06 | -0.15 | -0.61 | -0.19 | -0.46 |
| Investment in Securities | 1.15 | -148.26 | - | - | - |
| Investing Cash Flow | 1.96 | -148.41 | -0.61 | -0.19 | -0.46 |
| Issuance of Common Stock | 93.28 | 243.59 | 0.59 | 0.69 | 0.14 |
| Other Financing Activities | - | -9.3 | -2.39 | -1.71 | - |
| Financing Cash Flow | 93.28 | 234.29 | -1.8 | -1.02 | 130.51 |
| Net Cash Flow | 26.77 | 24.61 | -34.49 | -20.34 | 121.52 |
| Free Cash Flow | -68.53 | -61.42 | -32.69 | -19.33 | -8.99 |
| Free Cash Flow Per Share | -1.53 | -1.73 | -10.46 | -2.47 | -1.80 |
| Levered Free Cash Flow | -38.62 | -32.95 | -17.48 | -9.83 | - |
| Unlevered Free Cash Flow | -38.62 | -32.95 | -17.48 | -9.83 | - |
| Change in Net Working Capital | -5.16 | -5.38 | -2.23 | -3.8 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.